Literature DB >> 8839775

Lack of correlation of MLC reactivity with acute graft-versus-host disease and mortality in unrelated donor bone marrow transplantation.

M Segall1, H Noreen, L Edwins, R Haake, X O Shu, J Kersey.   

Abstract

Acute graft-versus-host disease (AGvHD) is a significant cause of morbidity and mortality in patients receiving a bone marrow transplant from an unrelated donor, and in an effort to reduce this problem, donors are selected for the least possible HLA incompatibility with the recipient. Selection criteria have included minimal incompatibility for the HLA-A, -B, and -DR loci and low reactivity in mixed lymphocyte culture (MLC); however, the value of MLC reactivity for prediction of development of AGvHD has been questioned. We therefore examined the correlation of MLC reactivity with AGvHD in recipients of unrelated bone marrow transplants. Reactivity in the GvH direction was assessed as relative response (RR) of donor lymphocytes to recipient stimulator lymphocytes. In 126 transplanted pairs with technically satisfactory MLC tests, the RR was divided into quartiles (0-1, 2-5, 6-16, and 17-117% RR). HLA-DRB1 incompatibilities were more frequent in the highest quartile (P < 0.001); there were no significant differences among quartiles in donor or recipient age, diagnosis, or frequency of HLA-A or -B incompatibility. Incidence of AGvHD during the first 100 days post-transplant was assessed by Kaplan-Meier analysis. There was no significant difference in incidence of AGvHD among quartiles for the entire group of 126 pairs, for a subset with hematologic malignancy, for a subset selected by a more stringent standard for "technically satisfactory" MLC, or for a subset matched for A, B, and DRB1. The MLC response of donor lymphocytes to recipient stimulator lymphocytes is thus not predictive of development of AGvHD in our patient population receiving unrelated donor bone marrow. Since there was no difference in mortality related to high and low MLC responses, our data also suggest that MLC results are not predictive of survival in this population.

Entities:  

Mesh:

Year:  1996        PMID: 8839775     DOI: 10.1016/0198-8859(96)00055-9

Source DB:  PubMed          Journal:  Hum Immunol        ISSN: 0198-8859            Impact factor:   2.850


  6 in total

1.  Role of ELISPOT Assays in Risk Assessment Pre- and Post-Kidney Transplantation.

Authors:  Jennifer R Zitzner; Anat R Tambur
Journal:  Cells       Date:  2012-05-10       Impact factor: 6.600

2.  Gene expression changes in HLA mismatched mixed lymphocyte cultures reveal genes associated with allorecognition.

Authors:  V Nicolaidou; C Stylianou; L Koumas; G S Vassiliou; K B Bodman-Smith; P Costeas
Journal:  Tissue Antigens       Date:  2015-04

3.  Virtual Global Transplant Laboratory Standard Operating Protocol for Donor Alloantigen-specific Interferon-gamma ELISPOT Assay.

Authors:  Robert Carroll; Alexander Troelnikov; Anita S Chong
Journal:  Transplant Direct       Date:  2016-10-20

Review 4.  A New Window into the Human Alloresponse.

Authors:  Susan DeWolf; Yufeng Shen; Megan Sykes
Journal:  Transplantation       Date:  2016-08       Impact factor: 4.939

5.  Immunological monitoring of renal transplant recipients to predict acute allograft rejection following the discontinuation of tacrolimus.

Authors:  Ellen Kreijveld; Hans J P M Koenen; Bram van Cranenbroek; Esther van Rijssen; Irma Joosten; Luuk B Hilbrands
Journal:  PLoS One       Date:  2008-07-16       Impact factor: 3.240

Review 6.  Strategies for Deliberate Induction of Immune Tolerance in Liver Transplantation: From Preclinical Models to Clinical Application.

Authors:  Naoki Tanimine; Masahiro Ohira; Hiroyuki Tahara; Kentaro Ide; Yuka Tanaka; Takashi Onoe; Hideki Ohdan
Journal:  Front Immunol       Date:  2020-07-31       Impact factor: 7.561

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.